Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Stroke, embolism, bleeding risk lower with apixaban vs rivaroxaban in nonvalvular AF

Roshini Claire Anthony
07 Apr 2020

Among patients with nonvalvular atrial fibrillation (AF), treatment with apixaban was associated with a lower rate of ischaemic stroke, systemic embolism, and major bleeding compared with rivaroxaban, according to a large study assessing patients in routine care.

Researchers of this retrospective study used data from the Optum Clinformatics database between 28 December 2012 and 1 January 2019 to identity adults with nonvalvular AF newly prescribed* apixaban 5 mg BID (n=59,172) or rivaroxaban 20 mg QD (n=40,706). Propensity score matching led to a study population of 39,351 new users of each drug (mean age 69 years, 40 percent female). Apixaban users were followed up for a mean 288 days, rivaroxaban users for a mean 291 days.

The incidence rate of ischaemic stroke or systemic embolism was lower among patients on apixaban compared with those on rivaroxaban (n=206 vs 251; 6.64 vs 8.01 per 1,000 person-years; hazard ratio [HR], 0.82, 95 percent confidence interval [CI], 0.68–0.98). [Ann Intern Med 2020;doi:10.7326/M19-2522]

Intracranial haemorrhage (ICH) or gastrointestinal (GI) bleeding also occurred at a lower rate among apixaban vs rivaroxaban recipients (12.94 vs 21.92 per 1,000 person-years; HR, 0.58, 95 percent CI, 0.52–0.66). This reduction was primarily driven by the lower incidence of GI bleeding in the apixaban vs rivaroxaban arms (9.35 vs 17.93 per 1,000 person-years; HR, 0.52, 95 percent CI, 0.45–0.59), with a comparable incidence of ICH between groups (3.64 vs 3.95 per 1,000 person-years; HR, 0.91, 95 percent CI, 0.71–1.18). Bleeding due to other causes was also reduced in the apixaban vs rivaroxaban arm (3.09 vs 5.26 per 1,000 person-years; HR, 0.58).

Hepatitis occurred at a similar rate in the apixaban and rivaroxaban arms (13.07 vs 12.34 per 1,000 person-years; HR, 1.05). Vasculitis was slightly less common with apixaban vs rivaroxaban (1.06 vs 1.21 per 1,000 person-years; HR, 0.86), though the researchers suggested the potential for a null effect, given the wide CIs (0.54–1.37).

The main effectiveness and safety findings persisted in an analysis of patients aged >70 years, a group with an elevated prevalence of AF. The rate of ischaemic stroke or systemic embolism was lower with apixaban compared with rivaroxaban (8.29 vs 10.46 per 1,000 person-years; HR, 0.79), as was the rate of GI bleeding and ICH (17.10 vs 30.02 per 1,000 person-years; HR, 0.57).

“[The results suggest that] apixaban may be safer and more effective than rivaroxaban for treating nonvalvular AF,” said the researchers.

Pertaining to the mechanism behind these findings, the researchers referenced a previous study that showed higher trough anti-factor Xa and lower peak anti-factor Xa activity with apixaban compared with rivaroxaban which may account for the lower risk of stroke and systemic embolism, and bleeding risk, respectively. [Clin Pharmacol 2014;6:179-187]

The lack of information on over-the-counter medication prescriptions was a limitation, they noted. They also pointed out that the findings are not representative of long-term outcomes of these two drugs.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.